Tiziana Life Sciences Ltd (TLSA) Form 6-K — Oct 16, 2026
Tiziana Life Sciences filed interim results for the six months ended June 30, 2026, reporting a total comprehensive loss of $12.4 million versus $5.3 million a year ago, with cash of $3.2 million at period end and $3.9 million as of October 16, 2026. The filing includes explicit going-concern language: directors state the company will not meet its liabilities as they fall due over the next 12 months without securing additional capital, and are exploring cost reductions and further equity raises.
Key figures
- Total Assets
- 11660000
- Cash Position
- 3178000
- Warrants issued
- 7040000
- Cash oct 16 2026
- 3900000
- Other receivables
- 6100000
- Shares outstanding
- 128028624
- Prior period net loss
- 5632000
- Total comprehensive loss
- 12400000
- Msa pet suv reduction pct
- up to ~35% (patients 1-2), up to 34% (patient 3)
- H1 2026 financing proceeds
- 6511000
- Ea program mfis improvers pct
- 64
- Prior year comprehensive loss
- 5300000
- Research development expense h1
- 6431000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.